MTOR and chronic myelogenous leukemia, BCR-ABL1 positive: Inconsistent Akt overactivation at Ser473 was also detected in imatinib-resistant CML patients, and imatinib resistance was decreased by mTOR inhibition only if AktSer473 was strongly activated [15].